George R. Blumenschein, MD
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
About Dr. Blumenschein
Dr. George R. Blumenschein, Jr. is a Professor of Medicine in the Department of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He received his B.A. from the Vanderbilt University and his M.D. from the University of Texas Medical School in Houston. He completed his residency in internal medicine at The University of Texas Health Science Center in Houston and his fellowship training in medical oncology at The University of Texas MD Anderson Cancer Center. Dr. Blumenschein is a member of ASCO, SITC, SWOG, RTOG, and AACR. He has authored or co-authored papers and book chapters regarding the management of lung and head and neck cancers. Dr. Blumenschein’s area of focus is in new drug development, adoptive T-cell therapy and multimodality therapy for the treatment of lung and head and neck cancers. Specifically, he is interested in the utilization of compounds with novel mechanisms of action in clinical trials for the treatment of these tumors. He is leading the Adoptive T-cell Program with the goal of developing this class of therapeutics for the treatment of Lung and Head and Neck Cancers. He serves as the principle investigator on a number of research protocols.
Education & Training
Degree-Granting Education
| 1994 | The University of Texas Health Science Center at Houston, Houston, TX, USA, MD, Medicine |
| 1987 | Vanderbilt University, Nashville, TN, USA, BA, Political Science |
Postgraduate Training
| 1997-2000 | Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1994-1997 | Clinical Residency, Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX |
Board Certifications
| 2003 | American Board of Internal Medicine, Medical Oncology |
| 1999 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Interim Section Chief, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023
Selected Publications
Peer-Reviewed Articles
- Tam A, Papadimitrakopoulou V, Wistuba I, Lee J, Ensor J, Kim E, Kalhor N, Blumenschein Jr GR, Tsao A, Heymach J, Herbst R, Hicks M, Hong W, Gupta S. The Value of Interventional Radiology in Clinical Trial Teams: Experience from the BATTLE Lung Cancer Trials. Clinical Radiology. e-Pub 2021. PMID: 33268083.
- Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR. A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers. Head Neck 37(5):644-649, 2015. e-Pub 2015. PMID: 24585506.
- Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget 5(19):8937-8946, 2014. PMID: 25313136.
- Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324. Radiother Oncol 112(1):30-6, 2014. e-Pub 2014. PMID: 25042878.
- Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 31(32):4105-14, 2013. e-Pub 2013. PMID: 24101053.
- Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378-384, 2013. e-Pub 2013. PMID: 23810431.
- Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small cell lung cancer (NSCLC). Ann Oncol 24(9):2382-9, 2013. e-Pub 2013. PMID: 23788751.
- Gonzalez-Angulo AM, Blumenschein GR. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39(4):313-20, 2013. e-Pub 2012. PMID: 23218708.
- Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of Image-Guided Transthoracic Core Needle Biopsy in the BATTLE Lung Trial. J Thorac Oncol 8(4):436-42, 2013. PMID: 23442309.
- Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome. Zhongguo Fei Ai Za Zhi 16(4):C9-20, 2013. PMID: 23601304.
- Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 2013. e-Pub 2012. PMID: 22736407.
- Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24(1):220-5, 2013. e-Pub 2012. PMID: 22898037.
- Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pre-treated NSCLC patients from the BATTLE trial. J Thorac Oncol 7(11):1645-52, 2012. PMID: 23059780.
- Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Brandon Gunn G, Lewin JS, Steinhaus GD, Sturgis EM. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck 34(9):1255-62, 2012. e-Pub 2011. PMID: 22009800.
- Blumenschein GR, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol 7(9):1406-16, 2012. PMID: 22743295.
- Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30(26):3287-96, 2012. e-Pub 2012. PMID: 22869872.
- Belani CP, Goss G, Blumenschein G. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 38(3):173-84, 2012. e-Pub 2011. PMID: 21715100.
- Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome. J Thorac Oncol 6(10):1763-1773, 2011. e-Pub 2011. PMID: 21876456.
- Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol 68(3):703-12, 2011. e-Pub 2010. PMID: 21140147.
- Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L, Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22(9):2057-67, 2011. e-Pub 2011. PMID: 21321086.
- Adjei AA, Blumenschein GR, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer 12(4):212-7, 2011. e-Pub 2011. PMID: 21726819.
- Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 2011. e-Pub 2010. PMID: 20094773.
- Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov 1(1):44-53, 2011. e-Pub 2011. PMID: 22586319.
- Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II Study of Cetuximab in Combination with Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324. J Clin Oncol 29(17):2312-8, 2011. e-Pub 2011. PMID: 21555682.
- Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II Study of Dasatinib in Patients with Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 28(30):4609-15, 2010. e-Pub 2010. PMID: 20855820.
- William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer 116(10):2409-15, 2010. e-Pub 2010. PMID: 20225329.
- Ross HJ, Blumenschein GR, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 16(6):1938-49, 2010. e-Pub 2010. PMID: 20215545.
- Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16(1):279-90, 2010. e-Pub 2009. PMID: 20028752.
- Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients with Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 27(26):4274-80, 2009. e-Pub 2009. PMID: 19652055.
- Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B. Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol 127(8):1074-5, 2009. PMID: 19667357.
- Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference opportunities for combination therapy. J Thorac Oncol 3((6 Suppl 2)):S107-12, 2008. PMID: 18520291.
- Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. A Randomized Phase III Trial Comparing Bexarotene (L1069-48) /Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (SPIRIT II). J Clin Oncol 26(11):1879-85, 2008. PMID: 18398153.
- Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. J Thorac Oncol 3(4):351-7, 2008. PMID: 18379352.
- Husain A, Blumenschein G, Esmaeli B. Treatment and Outcomes for Metastatic Sebaceous Cell Carcinoma of the Eyelid. Int J Dermatol 47(3):276-9, 2008. PMID: 18289332.
- Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-7, 2008. e-Pub 2007. PMID: 17960324.
- Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31(11):1645-52, 2007. PMID: 18059220.
Grant & Contract Support
| Title: | Phase I trial evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with solid tumors including but not limited to non-small cell lung cancer or hepatocellular carcinoma |
| Funding Source: | Immatics US Inc |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified August 01, 2024